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Abstract: Hemorrhage is the phenomenon of blood loss caused by vascular trauma or other pathological
reasons, which is life-threatening in severe cases. Because microhemorrhage is difficult to visually monitor and
pre-treat in vivo, it is necessary to establish in vitro prediction methods to study the hemostasis mechanism in
different physiological environments. In this study, a microfluidic bleeding model was developed to investigate
the effect of blood flow shear on microvascular hemostasis. The results indicated that the regulation of
blood shear rate on platelet aggregation affected the growth and morphology of hemostatic thrombus,
and finally regulated the process of hemostasis. This in vitro model is significant to studies on hemostatic
mechanisms, a reliable prediction of microhemorrhages, and an adjustment of the treatment scheme.
Keywords: microfluidic; hemostasis; platelet accumulation

1

Introduction

Hemorrhage is the phenomenon of blood loss caused
by vascular trauma or other pathological reasons,
which can endanger life in severe cases [1, 2]. Compared
to a ruptured macrovascular hemorrhage, a microhemorrhage, such as a gastrointestinal [3], hepatorrhagia
[4], and cerebral hemorrhage [5], is also often fatal.
Anticoagulant treatment, hypertension, advanced
age, and violent mood fluctuations, among other
factors, can easily cause a microhemorrhage, particularly
cerebral hemorrhage [6, 7]. Microhemorrhage in
the body can be subtle but dangerous. Some
gastrointestinal microbleeds are self-healing, but
there is also a risk of acute massive bleeding that
requires endoscopic therapy such as hemostatic
forceps, high-frequency radio coagulation, and
thrombin injections [3]. Cerebral hemorrhage is
difficult to control with external hemostatic
intervention, and can only be regulated by indirect

means, such as reducing the intracranial pressure
[7–9]. This is more dependent on the physiological
coagulation mechanism required for hemostasis.
Hemostasis is a physiological response to vascular
injury, during which blood clots form to seal the
wound and prevent blood loss [1]. The formation
of a hemostatic plug at sites of vascular injury relies
on the dynamical processes of platelet accumulation
and activation of the coagulation cascade in the
setting of the biorheology of blood flow [10]. When
the vessel is broken, the exposure of the blood to
the subendothelial matrix initiates platelets adhering
to the wound site through the von Willebrand factor
(vWF) and collagen or other extracellular matrix
protein binding, under hemodynamic shear conditions
of the blood flow [11, 12]. The adhesion activates
the platelets, which then triggers a suite of responses,
including the mobilization of binding receptors on
the platelet’s surface and the release of chemical
agonists into the blood plasma [13]. These agonists
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induce more active platelets, and the activated
platelets bind together to form a platelet embolism,
which is called platelet accumulation. The activation
of platelets and the exposure of the tissue factor
(TF) also initiate a coagulation cascade [1, 2]. Thrombin
is the major product of coagulation, which converts
the soluble plasma protein fibrinogen into insoluble
polymerized fibrin to form a stabilizing fibrin mesh
surrounding the deposited platelets. Finally, a stable
hemostatic plug is formed [2].
Because microhemorrhages are difficult to visually
monitor and pre-treat in vivo, it is necessary to
establish in vitro prediction methods to study
hemostasis mechanisms in different physiological
environments, which is significant for reliably
predicting a microhemorrhage and adjusting the
treatment scheme [14, 15]. In medicine, experimental
diagnostic methods for hemorrhagic diseases mainly
include the lengths of the bleeding, coagulation, the
activation of partial thromboplastin, prothrombin,
and thrombin [16]. These diagnostic methods can
predict hemorrhagic disease to a certain extent,
but in vitro single-factor monitoring ignores the
physiologic flow shear environment of hemostasis
problems. Some in vivo animal hemostasis models
show the direct global process of hemostasis at the
wound sites, but it is difficult to apply mechanistic
research at the intercellular level, which is limited
by the means of observation and variable control
[17, 18]. Owing to the recent advances in microfabrication technologies, microfluidic platforms have
been extensively used for microscale biological
and biochemical experiments, owing to their low
cost, high throughput, and good biocompatibility
[15, 19]. In vitro microfluidic models have been widely
used to study the mechanism of coagulation [2, 20] or
intravascular thrombosis [21, 22]. However, the
mechanism of intravascular thrombosis may not
directly translate into extravascular thrombosis,
which is relevant to bleeding blockage and hemostasis
[23, 24]. In vitro hemostasis models have been studied
relatively little. Schoeman et al. [23] presented a
microfluidic hemostasis model to assess the bleeding
time and explore the platelet function. To investigate
the interaction of different components of hemostasis
under altered microenvironments, Sakurai et al. [24]
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devised an ingenious microfluidic system coupled
with a microengineered pneumatic valve that
induces a vascular “injury”. However, both studies
only focused on major biological or biochemical
mechanisms of hemostasis and ignored the role of
blood flow in regulating the process of hemostasis.
A number of studies have shown that local flow
conditions have a crucial effect on the coagulation
and thrombosis processes [25–27]. Therefore, it is
necessary to construct a microvascular hemostasis
model in vitro to study the regulation of blood
flow in hemostasis.
Given this background, a microfluidic bleeding
model was developed to investigate the effect of
blood flow shear on microvascular hemostasis in
this study. The injury channel was coated with Type I
collagen to mimic the subendothelial matrix exposed
during vascular trauma and promote platelet adhesion
and coagulation. The blood flow is controlled to
mimic the flow shear bio-environment from venous
to arteriole (average wall shear rate of 100 ‒ 2,000 s‒1).
In this model, the entire process of microvascular
hemostasis can be monitored in real time, the hemostasis time is predicted well, and the regulation
mechanism of blood flow shear on hemostasis is
revealed. In conclusion, this microvascular hemostasis
model provides an ideal platform for studying
human blood samples and predicting hemostatic
and thrombotic diseases in vitro.

2
2.1

Materials and methods
Reagents and antibodies

Human CD41 monoclonal antibody FITC conjugate
and fibrinogen from human plasma Alexa Fluor
594 conjugate were purchased from Thermo Fisher
Scientific (China) Inc., Shanghai, China. Type I collagen
was purchased from Yeasen Biotechnology Co.,
Shanghai, China. A sodium citrate buffer, DiOC6,
and Dil were purchased from Solarbio Co., Beijing,
China. Anti-human vWF antibody conjugated with
fluorescein isothiocyanate (FITC) was purchased from
Rockland Immunochemicals Inc., Limerick, USA.
N-Acetyl-L-cysteine and bovine serum albumin (BSA)
were purchased from Sigma-Aldrich (Shanghai) Co.,
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Shanghai, China. Eptifibatide was purchased from
Shanghai Macklin Biochemical Co., Shanghai, China.
2.2

Microfluidic device design and construction

The microfluidic devices used in this study were
fabricated with polydimethylsiloxane (PDMS, Dow
Corning) using soft lithography techniques [28]. In
brief, the microfluidic channel mold made of SU-8
(Microchem, Co.) was patterned on a silicon wafer
using ultraviolet lithography (SF100, Advanced
Micro Patterning, Co.). The PDMS prepolymer was
mixed with the curing agent at a 10:1 ratio (w/w)
and poured onto the patterned silicon wafer
template. The mixture was cured in an oven at 70 ℃
for 1.5 h and peeled carefully from the wafer. Inlet
holes (diameter = 1 mm) were defined using a biopsy
puncher on the PDMS layer. The interior surfaces

of the PDMS layer, which had been oxidized by
exposure to plasma, were bonded to glass slides
cleaned in 1:1 12 M HCl:methanol for 1 h, rinsed
with 18.2 MΩ-cm deionized water and subsequently
dried using high-pressure air.
The microfluidic channel was designed in the
shape of the letter ‘H’ where the outer two horizontal
channels represent the vascular (blood perfusion
channel) and extravascular compartments (buffer
flush channel), respectively, and the horizontal
channels are connected using a vertical channel
representing the vascular wound (Fig. 1(b)) [23].
The width of the blood perfusion channel and the
buffer flush channel was 200 μm. The width of the
vascular wound channel was 50 μm, and the length
was 150 μm. The channel section has a consistent
height of 50 μm. The microfluidic bleeding model

Fig. 1 Microfluidic bleeding model of microvascular hemostasis: (a) Schematic of collagen coating layer preparation and main
channel anticoagulation; (b) bright field diagram of whole blood perfusion experiment; (c) blood flow pattern detected using
μPIV. (d) Real-time visualization of the entire hemostatic process from the 1,500 s‒1 group.. Fluorescent label: platelets (green)
and fibrin (ogen) (red).
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in this study applies to the microhemorrhage phenomenon occurring in the microcirculation system,
such as gastrointestinal, hepatorrhagia, and cerebral
hemorrhages because the microvessels that are
distributed at these microhemorrhage sites have
diameters ranging from tens to hundreds of microns
[3–6, 23–24]. The microscale of the microfluid bleeding
model can present a stable laminar flow, which enables
the shear stress to be strictly controlled and regulated,
thus achieving the dynamic physiological range of
the microcirculation.
Type I collagen (0.5 mg·ml‒1) [22] was adsorbed
into the walls of the vascular wound channel, as
shown in Fig. 1(a). Using a pipette, a 10-μL collagen
solution was drained and slowly injected into the
inlet of the buffer flush channel while the blood
perfusion channel was empty. The wound channel
was then filled, although the solution was contained
in the wound channel owing to capillary forces at
the solution–air interface between the wound and
blood channels. Collagen solutions were allowed
to adsorb on the walls of the wound channel at 4 ℃
for 12 h. Prior to the perfusion of blood, the blood
channel was blocked with 2% BSA in phosphate buffer
solution (PBS) for 1 h to increase the anticoagulation.
2.3

Blood collection and preparation

Whole blood was collected from healthy donors
using a venepuncture and stored in vacutainer tubes
containing 3.2% sodium citrate to prevent coagulation.
All procedures involving human participants were
conducted in compliance with the relevant laws
and guidelines approved by the Institutional
Review Board (IRB) of Tsinghua University (No.
20200036), and with the 1964 Helsinki declaration
and its later amendments. Alexa-594 labeled human
fibrinogen (final concentration of 12.5 μg·mL‒1)
was added to the collected blood to visualize the
deposition of the fibrin. Platelets were labeled with
an FITC-conjugated CD41 monoclonal antibody
(final concentration of 5 μg·mL‒1, with green
fluorescence) or Dil (final concentration of 1 μg·mL‒1,
with red fluorescence). vWF was stained with FITCconjugated vWF antibody (final concentration of
1 μg·mL‒1). The labeled blood was incubated at 37 ℃
in the presence or absence of eptifibatide (50 μg·mL‒1)
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or NAC (30 mM) for 15 min prior to the assay. Before
the perfusion experiment, the labeled blood was treated
by rapidly mixing the blood with a recalcification
buffer at a ratio of 9:1 to restore the coagulation,
which was prepared by dissolving 75 mM of CaCl2
and 35 mM of MgCl2 in a PBS. During the experiment,
labeled recalculated whole blood was perfused
into the blood perfusion channel at a controlled
flow rate (0.5, 2.5, 5, 7.5, 10 μL·min‒1) to simulate
the average wall shear rate (100, 500, 1,000, 1,500,
and 2,000 s‒1) of blood flow under different physiological conditions from the veins to the arteries. A
sodium citrate buffer was perfused into the buffer
flush channel at half the blood flow rate to simulate
the extravascular compartments.
2.4

Measurement system and methods

Red blood cells (RBCs) with a hematocrit of 0.5% in
PBS were directly used as tracer particles to show
the flow field in a bright field under an inverted
microscope (IX83, Olympus Co.). The motion of the
RBCs was recorded using a high-speed camera (M110,
Phantom Co.). The recorded videos were analyzed
using μPIV software (DynamicStudio, Dantec Co.)
to acquire the velocity field in the microfluidic
bleeding model (Fig. 1(c)). The hemostasis processes
under different flow conditions were measured
using a fluorescence microscope (IX83, Olympus
Co.). Image J (National Institutes of Health) was
used to calculate the coverage area of hemostatic
thrombosis in the wound channel.

3

Results and discussion

3.1 Characterization of in vitro microfluidic bleeding
and hemostasis model
A polydimethylsiloxane (PDMS)-based microfluidic
device was used to simulate in vitro microvascular
bleeding. Two horizontal channels of the “H” shaped
microfluidic channel represent the vascular (blood
perfusion channel) and extravascular compartments
(buffer flush channel), respectively, and the vertical
connection channel represents the vascular wound
(Fig. 1(b)). Physiologically, damaged blood vessel
walls expose the subendothelial matrix rich in
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adhesive and procoagulant proteins that support
thrombus formation. In this model, the internal
surface of the wound channel is precoated with Type I
collagen, which is abundant in the subcutaneous
matrix, and the blood channel was precoated with
BSA (Fig. 1(a)). Type I collagen is a strong agonist
and adhesive ligand for platelets through the GPVI
and integrin α2β1 [29]. The endothelial surface of
the blood vessel is replaced by a BSA layer coated
on the internal surface of the blood channel, which
played a certain antithrombotic role [23]. During
the experiment, re-calcified sodium citrate-treated
whole blood was perfused through the device at a
controlled flow rate, and the average wall shear
rate achieved (100, 500, 1,000, 1,500, 2,000 s‒1) can
approximately simulate the blood shear environment
within the physiological range from the veins to
the arteries and arteriloes [2, 12]. According to the
μPIV flow field analysis (Fig. 1(c)), the blood flow
forms a high-speed flow area in the inlet and outlet
of the wound channel, which will wash away the
hemostatic thrombus formed and reduce the local
concentration of procoagulant substances. Real-time
monitoring of hemostasis can then be performed
through fluorescence microscopy, and the hemostasis
time (defined as the time at which red blood cells
stop transiting into the extravascular area) and
fluorescence coverage area of relevant biological
species are then monitored. Figure 1(d) shows the
whole process of hemostatic thrombus from initiation
and growth up to hemostasis achieved under a
flow condition of 1,500 s‒1. Because the blood is continuously perfused into the blood channel, it also flows
through the wound channel into the extravascular
channel, similar to “bleeding” (Fig. 1(b)). As blood
flows through the wound channel, platelets adhere
throughout the mimic injury site, and platelet aggregation and fibrin polymerization lead to the formation
of a hemostatic plug at the wound site. The hemostatic
thrombus continues to grow until the wound channel
is blocked and the bleeding stops (Fig. 1(d)). In this
group, the hemostasis time was 15.5 min.
3.2 Process of hemostasis under different blood flow
shear rates
The hemostasis time and hemostatic process under

different shear rates are shown in Fig. 2. In the
hemostasis model of the same size, when the shear
rate of blood flow increased from 100 to 2,000 s‒1, the
hemostasis time changed, as shown in Fig. 2(a). It
can clearly be seen that, at the lowest (100 s‒1) and
highest (2,000 s‒1) shear rates, the hemostasis time
was relatively short, at approximately 17.0 and 14.2
min, respectively. However, at the intermediate shear
rate (1,000 s‒1), the wound cannot be completely
blocked after 30 min, and hemostatic failure occurs.
Figures 2(b) and 2(c) show the fluorescence coverage
of platelets and fibrin in hemostatic thrombus at
different shear rates with an increase in the hemostatic
time. Figure 2(d) shows the area fraction of hemostatic
thrombus at different shear rates when hemostasis
was achieved (data at 1,000 s‒1 was obtained after
blood perfusion for 30 min). As can be seen, when
the shear rate increased from 100 to 1,000 s‒1, the
coverage area of the platelets and fibrin in the
hemostatic thrombus gradually decreased; when
the shear rate increased from 1,000 to 2,000 s‒1, the
coverage area of both increased gradually. The growth
rate of hemostatic thrombus was also affected by
shear rate. At an intermediate shear rate (1,000 s ‒1),
the coverage area of hemostatic thrombosis was
the smallest, the growth rate was the slowest, the
hemostatic time was the longest, and a hemostatic
failure occurred. At a low shear rate (100 s‒1) similar
to a venous environment, the fibrin coverage is the
largest, the growth is the fastest, and the hemostasis
time is shorter. At a high shear rate (2,000 s‒1) similar
to the arteriole environment, the platelet coverage
area is the largest, the growth rate is the fastest,
and the hemostasis time is the shortest.
Because the geometric size of the hemostasis model
is unchanged, with an increase in the shear rate, the
scouring effect of blood flow on the wound channel
and the dilution effect on the local concentration of
coagulant should be gradually enhanced. However,
the occurrence of an intermediate shear rate, which
is prone to hemostatic failure, indicates that the
hemostatic mechanism is also influenced and regulated
by the shear rate of blood flow. It is clearly shown
in Fig. 2(d) that the coverage of fibrin in each
experimental group was not significantly different.
Except for the low coverage fraction (approximately
60%) in the hemostasis failure group, the coverage
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Fig. 2 (a) Wound closure time at different shear rates of blood flow; (b) growth of hemostatic thrombus at different shear rates
(platelet and fibrin coverage area fraction; “|” indicates that hemostasis is achieved, and “×” and hollow symbols indicate a
hemostasis failure); (c) growth of hemostatic thrombus at different shear rates (fibrin coverage area fraction); (d) area fraction
of hemostatic thrombus at different shear rates when hemostasis is achieved. It should be noted that the data at 1,000 s‒1 was
obtained after blood perfusion for 30 min, indicating a hemostatic failure.

fractions in all other groups were more than 80%.
However, there were significant differences in platelet
coverage between groups. These results suggest
that the difference in the hemostasis process under
different flow shear rates is related to the platelet
aggregation mechanism. The propensity of platelets
to clump together at sites of vascular injury is described
as platelet aggregation, and it is now widely accepted
that one of the key elements influencing the platelet
aggregation process is blood flow, with evidence
that distinct aggregation mechanisms operate under
different shear conditions [12, 30]. The following
sections describe how the shear-condition-mediated
platelet aggregation affects the hemostasis process.
3.3

Mechanism of flow-mediated platelet accumulation on microvascular hemostasis

Based on findings from in vitro perfusion experiments
[10, 22, 24] and in vivo thrombosis models [18, 26],

multiple adhesion receptors and ligands are involved
in platelet aggregation, the most important of which
include vWF, fibrinogen, and integrin αIIbβ3. Here,
vWF is a large multimeric protein essential for platelet
adhesion under arterial flow conditions. The potential
shear-dependent changes in the globular conformation
of vWF can lead vWF to unfold upon the application
of the fluid shear and increase the availability of
receptor binding sites for platelets [13, 25, 26]. Integrin
αIIbβ3 is a membrane-bound platelet receptor, and
fibrinogen acts as a soluble adhesive protein; the
interactions between them have also been demonstrated to support platelet aggregation [26, 30]. The
relative effects of each mechanism on the hemostasis
process under major shear conditions are experimentally
studied.
The distribution of platelets and vWF in hemostasis
thrombus after 15 min of blood perfusion at 100,
1,000, and 2,000 s‒1 was experimentally observed to
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investigate the role of vWF in platelet aggregation
under different shear conditions. It is clearly demonstrated in Fig. 3(a) that, as the shear rate of blood flow
increases, vWF gradually dominates the platelet
aggregation. At 100 s‒1, platelets aggregated in the
middle of the wound channel and eventually formed
a blocking embolism, but no vWF distribution was
found, suggesting that vWF did not play a role in
platelet aggregation at a lower shear rate. At 1,000 s‒1,
platelets accumulated in the medial wall and downstream of the wound channel, but did not form a
complete clumpy embolism to block the channel.
The vWF distribution area is slightly narrower
than that of the platelets, suggesting that vWF is
partially involved in platelet aggregation at the
intermediate shear rate. In fact, the distribution of

platelets and vWF in this group remained in this
state until the perfusion experiment was carried
out for 30 min, and hemostasis was not achieved.
At 2,000 s‒1, a large number of platelets accumulated
in the interior and outlet of the wound channel,
eventually completely blocking the wound channel.
vWF is also present in large numbers, and the distribution area basically overlaps with the platelets,
which means that vWF dominates the platelet
aggregation at a higher shear rate.
From the results shown in Fig. 3(a), it can be inferred
that vWF dominates the platelet aggregation in a
high-shear state, whereas in a low-shear state, it is
most likely dominated by another mechanism,
integrin αIIbβ3-fibrinogen interactions. Large number
of previously published studies on thrombosis have

Fig. 3 (a) As the shear rate of blood flow increases, vWF gradually dominates the platelet aggregation; fluorescent label: vWF
(green) and platelet (orange red), respectively. (b) Mechanism of flow-mediated platelet accumulation on microvascular
hemostasis.
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shown that the platelet aggregation mechanism is
regulated by the blood flow shear [25–27, 31].
Studies on the mechanism of platelet aggregation
[26, 30] indicate that, under conditions of relatively
low shear (0–1,000 s‒1), platelet aggregation is primarily
mediated by soluble fibrinogen, which physically
cross-links platelets through the engagement of
integrin αIIbβ3, which is affected by the local concentration of fibrinogen; in addition, at progressively
higher wall shear rates (> 1,000 s‒1), the aggregation
becomes more vWF-dependent, and plasma vWF
binds to the platelet receptor GPIb, leading to platelet
activation and subsequent shear-induced platelet
aggregation. Studies of plasma fibrinogen and
platelet integrin αIIbβ3 [32, 33] support the above
viewpoints, suggesting that under relatively low
shear conditions (< 1,000 s‒1), integrin αIIbβ3 on the
surface of free-flowing platelets can engage fibrinogen
adsorbed onto the surface of the thrombus; in
addition, the subsequent stimulation of platelets
by locally generated soluble agonists induces a
platelet shape change and an increase in integrin
αIIbβ3 affinity, which helps stabilize and sustain
integrin αIIbβ3-fibrinogen bonds. Studies on plasma
vWF [25, 27, 31] also showed that, at a low shear of
< 30 dyn·cm‒2 (converted into a shear rate of ~187 s‒1,
when considering that the blood viscosity in this
model is 1.6 × 10‒2 Pa·s, which is estimated from the
empirical relationship for blood flow in tubes with
diameters of < 1 mm [34]), vWF remains inactive.
When the shear increases beyond 80 dyn·cm‒2 (~500 s‒1),
vWF polymerization occurs and begins to induce
platelet aggregation; the mechanisms mediated by
integrin αIIbβ3 and vWF are not mutually exclusive,
and both operate within the intermediate shear range;
at an extremely high pathological shear level of >
300 dyn·cm‒2 (~1875 s‒1), the relative contribution
of vWF to thrombosis increased significantly and
eventually replaced integrin αIIbβ3 as the main
mechanism.
From the above information, it can be seen that
the regulation of blood shear rate on platelet
aggregation affects the growth and morphology of
hemostatic thrombus, and finally regulates the
process of hemostasis. The detailed mechanism is
shown in Fig. 3(b). At a low shear rate (100 s‒1)
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similar with the venous environment, the dominant
mechanism is an integrin αIIbβ3-fibrinogen interaction.
The integrin αIIbβ3-fibrinogen bond is a long-lived,
powerful bond with a small koff (dissociation rate)
of 0.15–0.25 s−1 under the action of dissociation
produced by a low shear flow [12, 35]. Under this
condition, platelets move slowly and have sufficient
response time to form this powerful bond. Therefore,
an integrin αIIbβ3-fibrinogen bond can mediate the
formation of a strong adhesion of platelets on the
surface of the wounds. The slow blood flow is also
conducive to the local increase in the concentration of
fibrinogen and other coagulants in the wound
channel, and the platelets can aggregate in clumps
to form stable hemostatic thrombi. At an intermediate
shear rate (1,000 s‒1), platelets move faster and do
not have an adequate response time, and fibrinogen
and other coagulants have difficulty maintaining a
relatively high concentration in the wound channel
at an increasing flow rate, and thus the integrin
αIIbβ3-fibrinogen mechanism has difficulty in playing
a good role. At the same time, this shear rate also
makes it difficult for the vWF-mediated mechanism
to fully play its role, and thus it is difficult for
platelets to aggregate to block the entire channel,
and a hemostasis failure is likely to occur. At a high
shear rate (2,000 s ‒1 ) similar with the arteriole environment, the vWF-mediated mechanism dominates
and plays a full role. Large amounts of vWF unfold
into long chains under a high fluid shear and adhere
to the wound channel, activating and binding a large
number of platelets to form a platelet embolism
sufficient to block the wound. By contrast, the bond
between vWF and platelets is a transient weak bond.
First, transient bonds form between inactivated
platelets in the blood flow and vWF adheres to the
wound surface. The vWF-GPIb bonds form rapidly,
but also dissociate rapidly, and slow the platelets down,
allowing them to roll slowly over the surface of
the thrombus [26], allowing time to activate them
and enable the formation of longer-lived and strong
αIIbβ3-mediated bonds. The koff of the vWF-GPIb
bond is usually greater than 3 s−1 [36] and is much
larger than that of the integrin-fibrinogen bond.
Under high shear conditions, the high dissociation
rate of the vWF–GPIb bond indicates that more
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platelets per unit of time have opportunity to be
captured by vWF, slow down to stop on the surface of
the wound or form a thrombus, and finally form
adhesion an stable and aggregation [12, 36]. This is
the main reason why vWF-mediated mechanisms
play a dominant role in high shear.
Although surprisingly, platelet aggregation has
difficulty in occurring, and the hemostatic time is
prolonged within the intermediate shear range,
similar findings have been reported in published
studies on intravascular thrombosis. Neeves compared
platelet aggregation on Type I collagen at shear rates
of 126, 492, and 1,260 s‒1 [37] and at 150, 300, 750, and
1,500 s‒1 [38] using in vitro models of intravascular
thrombosis, and found the platelet aggregation to
decrease over 1,000 s‒1. In addition, Neeves et al. [37, 38]
pointed out that this could be the result of competitive
effects, i.e., an increase in blood flow increased the
platelet flux, but also increased the adhesion bond
force load, reduced the interaction time, and diluted
the active coagulant substances, resulting in less
efficient platelet adhesion and aggregation at higher
flow rates. However, these studies did not
consider the differences in platelet aggregation
mechanisms at different shear rates, nor did they
examine the situation in which the shear rate
continued to increase. There are some differences
between hemostasis and intravascular thrombosis
in the blood flow pattern and the thrombus growth
environment, although the coagulation mechanism
of the two is the same, and thus a similar shearmediated platelet aggregation may occur.
However, in actual physiological situations, the
evolution of biological systems does not result in a
range of blood flow shear rates that are prone to
hemostatic failure. This is because the physiological
endovascular environment is much more complex
than in the hemostatic model focused solely on platelet
aggregation. First, this model only considers the
intrinsic coagulation pathway induced by the presence
of Type I collagen at the wound site, which is also
the most important pathway for platelet adhesion
and aggregation [10–12]; however, there are many
other pro-coagulant substances in the subendothelial
matrix exposed at the vascular wound. Tissue factor
(TF) is the most important one. The TF is the initiator
of the extrinsic pathway of coagulation, when the

TF is exposed to plasma proteins from the wound,
it will bond the clotting factor VII (factor VII, FVII) to
trigger a blood coagulation cascade [39, 40.] Therefore,
the presence of TF during the actual hemostasis
process will also accelerate and enhance the growth
of the hemostatic thrombus, thus reducing the
hemostasis time. Second, in addition to the above
mechanisms, other adhesion receptors and ligands
are also involved in platelet aggregation, such as
fibronectin. Initially, fibronectin was thought to
play a minor role in platelet aggregation, but in
vivo studies from Ni et al. [41] showed that persistent
thrombosis was seen in the arterioles of mice lacking
vWF and fibrinogen, suggesting a third adhesive
ligand involved in platelet aggregation. Subsequent
studies in mice with low fibronectin expression have
confirmed the important role of fibronectin in promoting platelet aggregation and thrombus growth
[30, 42]. Fibrinolytic proteins may cooperatively
enhance platelet adhesion, aggregation, and thrombus
growth by cross-linking with polymerized fibrin,
but their role in shear-dependent platelet aggregation
is not fully understood, and therefore its role is not
considered in the present study. Finally, in addition
to platelet aggregation, the flow shear rate also
influences the initial adhesion of platelets at the
wound site and subsequent procoagulant action
[26, 29, 30]; however, this study only considers the
effect of shear-mediated platelet aggregation on
the hemostatic process. Therefore, hemostatic failure
does not easily occur under normal physiological
conditions, whereas the mechanism of shear-mediated
platelet aggregation can affect the hemostatic process
and hemostatic time to a certain extent, and is likely
to have a significant impact under some special
pathological conditions (such as vascular hemophilia
and other coagulation disorders).
3.4 Hemostasis under altered microenvironments
To verify the effect of integrin αIIbβ3-fibrinogen and
vWF mechanisms on hemostasis under low shear
and high shear conditions, the corresponding inhibitors
were used to change the blood microenvironments.
Tryptopeptide (50 μg·mL‒1) was added to the whole
blood to investigate the effect of integrin αIIbβ3 on
hemostasis at a low shear rate (100 s‒1). Eptifibatide is
a common anti-platelet agent that inhibits integrin
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αIIbβ3. As shown in Figs. 4(a1) and 4(a2), in the control
group, as soon as platelets adhere and aggregate at
the wound site, fibrin rapidly accumulates and grows,
eventually forming a stable hemostatic thrombus
with a large amount of fibrin and small amounts of
platelets, similar with the composition of venous
thrombosis [39], and hemostasis was achieved in
15 min. In the eptifibatide-treated group, platelets
can still adhere to the collagenous coating of the
wound channel as plaques but cannot form clumps
of platelet aggregation embolism. Because the
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platelet surface is the main site of coagulation and
fibrin network formation [2, 10], the coverage area
of fibrin is significantly reduced and is unable to
form a sufficiently stable hemostatic thrombus,
resulting in hemostatic failure. The results confirm
that integrin αIIbβ3-mediated platelet aggregation
regulates the hemostasis process at low shear rates.
In this study, 30 mM N-Acetyl-L-Cysteine (NAC)
was added to the whole blood to investigate the
effect of vWF on the hemostasis at a high shear
rate (2,000 s‒1). NAC is an antioxidant that inhibits

Fig. 4 (a1) At 100 s‒1, growth of hemostatic thrombus in the control group and eptifibatide-treated group; (a2) after
eptifibatide treatment, platelet aggregation was significantly decreased compared with the control group, indicating that integrin
α IIbβ3 mediates platelet aggregation under low shear conditions and thus affects the hemostasis process; (b1) at 2,000 s ‒1, growth
of hemostatic thrombus in the control and NAC-treated groups; (b2) after NAC treatment, platelet aggregation mostly
disappeared compared with the control group, indicating that vWF mediates platelet aggregation under high shear conditions
and thus affects the hemostasis process. Fluorescently label: platelets (green) and fibrin (ogen) (red), respectively.
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vWF activity by interfering with disulfide bonding,
thereby preventing vWF-mediated thrombosis [31].
As shown in Figs. 4(b1) and (b2), in the control
group, platelet adhesion and aggregation occurred
rapidly in the wound channel after the beginning
of the experiment. However, owing to the high
blood flow rate and the low local concentration of
fibrinogen, the formation of the fibrin network is
slow, and the formed platelet embolism is not
sufficiently stable and is easy to wash away.
Therefore, the platelet coverage area fluctuates
within the first 5 min. After 5 min, with the
formation of the fibrin network, stable hemostatic
thrombus begins to form, and the coverage area of
the platelets and fibrin increases rapidly. Finally,
hemostatic thrombus rich in platelets and fibrin
forms, and hemostasis is achieved within 13 min.
In the NAC-treated group, owing to the inhibition
of the vWF function, only a small platelet embolism
can form at the corner of the passage, and there is
almost no platelet distribution inside the wound
channel. In the absence of platelets, a fibrin network
is difficult to form at such a high shear rate, and
the coverage is almost zero, resulting in hemostatic
failure. The results further confirm that vWF-mediated
platelet aggregation regulates the hemostasis process
at high shear rates.
3.5 Discussion on accelerating hemostasis methods
It can be seen from the above results that in the intermediate shear rate range (~1,000 s‒1), the hemostatic
effect of integrin-fibrinogen and a vWF-mediated
platelet aggregation mechanism cannot be fully
exerted, and thus hemostatic failure is likely to
occur. To improve this failure, two approaches can
be used to improve the efficiency of hemostasis by
adjusting the shear condition of the blood flow at
the vascular wound and provide an exogenous
coagulant. Conventional methods such as sutures
[43], hemostats, sealants, and tissue adhesives [44],
can apply pressure to the wound to slow the flow
of blood loss and reduce the blood flow shear, thus
promoting hemostasis. These methods are suitable
for hemostasis of trauma with large wounds, but
are not suitable for the microhemorrhage mentioned
in this study. Hemostatic gauze and dressings are

used for the treatment of a microhemorrhage on
the tissue surfaces, which can not only reduce the
flow rate of blood loss by applying pressure, but also
provide a leakage channel for lost blood owing to its
porous nature, further reducing the flow rate of blood
loss by dispersing the flow and increasing the
contact area of the blood, and thus further promoting
hemostasis [45, 46]. However, the hemostatic devices
mentioned above lack the biological activity to activate
platelets and trigger a coagulation cascade. Inorganic
mesostructured materials, including mesoporous
SiO2 [47], mesoporous bioactive glasses [48], microporous aluminosilicates [49], and their composites
have recently been widely used in the field of
hemostasis owing to their highly mesoporous
structure and procoagulation surface. Biomaterials
with biocoagulation-promoting activities, such as
gelatin [50, 51] and chitosan [52, 53], have been
developed into various forms of hemostatic materials
such as sponges, hydrogels, and nanoparticles, and
have been widely used depending on their rapid
activation of the platelets and coagulation cascade
reactions [50–53]. The cold atmospheric plasma (CAP),
which contains an abundant reactive oxygen species,
active nitrogen, and other active groups that can
promote blood coagulation, allows for effective
blood coagulation without thermal effects, and has
wide application potential in the treatment of a
microhemorrhage such as an errhysis and a
gastrointestinal hemorrhage [54, 55].

4

Conclusions

In this study, a microfluidic bleeding model was
developed to investigate the effect of blood flow shear
on microvascular hemostasis. The blood flow is
controlled to mimic the flow shear bioenvironment
from the venous to the arteriole. The presence of the
intermediate shear rate, which is prone to hemostasis
failure, suggests that microvascular hemostasis is
influenced and regulated by the flow shear. Based
on the growth process and composition distribution
of hemostatic thrombus, it was found that blood
shear can affect the growth and morphology of
hemostatic thrombus by regulating the platelet
aggregation, and finally regulate the hemostatic
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process. At low shear rates, the dominant mechanism
of platelet aggregation is the integrin αIIbβ3-fibrinogen
interaction. At a high shear rate, the vWF-mediated
mechanism dominates. At an intermediate shear
rate, the scouring of faster blood flow makes it
difficult for fibrinogen and other coagulants to
maintain a relatively high concentration, and the
integrin αIIbβ3-fibrinogen mechanism has difficulty
in playing a good role. This shear rate also makes
it difficult to apply the vWF-mediated mechanism.
As a result, it is difficult for platelets to aggregate
into embolisms that can block the entire channel,
and hemostasis failure is likely to occur. The results
of the hemostasis process with an altered microenvironment using two inhibitors, eptifibatide and
NAC, further confirmed the shear-mediated dominant
platelet aggregation mechanism. Consequently,
the microfluidic bleeding model in this study may be
used to study the hemostasis mechanism in different
physiological environments, which is of significance
for the reliable prediction of a microhemorrhage
and an adjustment of the treatment scheme.
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